LigaChem Bio Secures 14.1 Billion Won Milestone From Ono
7h agoen
From the article
LigaChem Biosciences will receive a milestone payment of at least 14.1 billion won from Ono Pharmaceutical after the first patient dosing of LCB97, an L1CAM-targeting ADC in Phase 1 trials.
Continue reading on Seoul Economic DailyYou might also wanna read
Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet
EU-Startups·3h ago
Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline
Fierce Biotech·3d ago
RQ Bio secures $115M Series A for virus-targeting antibody pipeline
endpoints.news·14d ago
Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference
Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre
avacta.com·14d ago
Nura raises $73.8M to target ALS through a unique target
biospace.com·16d ago
Beckman Coulter grows Alzheimer’s dx portfolio with CE mark for new assay
Fierce Biotech·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.